Biogen

The company has signed an agreement with biopharmaceutical firm SuppreMol to use its UNIarray technology to identify autoantibody signatures of SLE patients enrolled in a phase IIa study of SuppreMol's lead therapeutic SM101.

Unilabs will develop a two-step ELISA test to detect anti-JCV antibodies to help stratify patients receiving Biogen Idec's Tysabri (natalizumab).

The company will use its UNIarray protein array platform to retrospectively analyze samples from a clinical trial in hopes of finding predictive and response biomarkers for relapsing/remitting multiple sclerosis.

Protagen will use its UniArray protein-chip platform and expertise in autoantibody research to retrospectively analyze samples from a Biogen Idec clinical trial to identify predictive and response biomarkers associated with MS therapies.

Under the terms of an agreement, Protagen's UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS.

Rosetta Genomics top executive said this week that the firm expects to forge at least one strategic partnership by year end, although he did not specify whether it would be around its diagnostics, drug research biomarker, or therapeutics efforts.

Biogen Idec worked with Gene Network Sciences to integrate and analyze genome-wide SNP data, expression data, and clinical data from three time points in more than 70 rheumatoid arthritis patients — a process that ultimately identified several targets, including one "that had not been on the radar screen."

Evotec will screen a target and develop assays for Biogen Idec.

While many firms have successfully met their goals of allying with big pharmas and biotechs, others have failed to do so, despite promises of forthcoming deals.

It was not clear whether the potential diagnostic would be based on microRNA expression patterns. Last year, Asuragen began marketing an miRNA-based test for differentiating pancreatitis from pancreatic ductal adenocarcinoma.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.